Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $337.45M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.41M
Average 1.73M
LRMR Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Larimar Therapeutics, Inc.NASDAQ: LRMR
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $1.5M fell 21.1% year over year, ahead of the -36.5% change in trailing-twelve-month other income / expenses. Sequentially, it fell 1.1% from the prior quarter. Over 3 fiscal years it compounded at +80.0% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -21.1% holds above the trailing-twelve-month pace of -36.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 6.82M USD
- Year-over-year change
- -33.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.82M | -33.7% |
| FY2024 | 2024-12-31 | 10.29M | +113.9% |
| FY2023 | 2023-12-31 | 4.81M | +310.7% |
| FY2022 | 2022-12-31 | 1.17M | +784.8% |
| FY2021 | 2021-12-31 | (171K) | — |
Other Income / Expenses vs competitors
How LRMR compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -36.5% is the 4th highest of 11, against a peer median of -63.8%.
- Over three fiscal years its annual growth of +80.0% compares with a peer median of +33.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $10.28M USD | +47.5% | +96.1% | — |
| LTM Mar 2026 | $8.58M USD | -44.7% | +38.6% | — | |
| LTM Mar 2026 | $7.39M USD | -51.5% | +158.9% | — | |
| LTM Mar 2026 | $6.42M USD | -36.5% | +80.0% | — | |
| LTM Mar 2026 | $5.84M USD | -19.7% | +26.4% | 16213.9% | |
| LTM Mar 2026 | $2.64M USD | -79.4% | — | 1.2% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $1.99M USD | -76.1% | — | — |
| LTM Mar 2026 | $1.55M USD | +54.4% | +12.0% | — | |
| LTM Mar 2026 | -CHF 1.47M CHF | -268.3% | — | 39.8% | |
| LTM Mar 2026 | -$30.01M USD | -466.4% | — | 781.1% | |
| LTM Mar 2026 | -$129.21M USD | -2023.6% | +28.2% | — | |
| Peer median (excluding LRMR) | — | -63.8% | +33.4% | 410.4% | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.4M | 24.25M | 27.67M | 73.28M | 154.22M |
| Selling, General & Admin | 12.07M | 12.28M | 14.09M | 17.61M | 18.27M |
| Operating Expenses | 50.47M | 36.53M | 41.76M | 90.89M | 172.5M |
| Depreciation & Amortization | 326K | 318K | 311K | 318K | 350K |
| EBITDA | (50.31M) | (35.04M) | (36.64M) | (80.29M) | (165.32M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.47M) | (36.53M) | (41.76M) | (90.89M) | (172.5M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (171K) | 1.17M | 4.81M | 10.29M | 6.82M |
| Income Before Tax | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| EPS (Diluted) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| Weighted Avg Shares | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
| Weighted Avg Shares (Diluted) | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$3.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.